Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6
Conclusion. Due to the good toxicity profile and the oral administration, combined therapy with momelotinib and citarinostat may represent a promising novel therapeutic modality for hematological malignancies. The study is ongoing and further investigation is required.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Cosenza, M., Civallero, M., Sacchi, S., Pozzi, S. Tags: 802. Chemical Biology and Experimental Therapeutics: Poster II Source Type: research
More News: Biology | Cancer & Oncology | Chemistry | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Cutaneous T cell lymphoma | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Mitochondria | Mitochondrial Disease | Myeloma | Myeloproliferative Disorders | Study | T-cell Lymphoma | Toxicology